Abstract
Purpose
The objective of the work was to evaluate the potential of hyaluronan-based nanoparticles as tumor-targeting nano-systems for CD44-overexpressed cancer therapy.Methods
The synthesized amphiphilic cholesteryl succinoyl hyaluronan (Chol-Suc-HA) conjugates self-assembled into docetaxel(DTX)-loaded nanoparticles in the aqueous environment. The physiochemical properties of Chol-Suc-HA-DTX NPs were characterized. The in vitro cytotoxicity of Chol-Suc-HA-DTX NPs against MCF-7, 4T1, A549 and L929 cells was evaluated using MTT and LDH assays. Moreover, the cellular uptake mechanism was investigated using the CLSM and flow cytometry. The in vivo animal experiments of Chol-Suc-HA-DTX NPs including pharmacokinetic evaluation, bio-distribution observed by EX vivo NIRF imaging and antitumor efficacy were also carried out in SD rats or 4T1 tumor-bearing BALB/c mice.Results
The self-assembled Chol-Suc-HA-DTX NPs with different degree of substitution (DS) of hydrophobic moiety exhibited high drug loading, uniform particle size distribution and excellent in vitro stability. However, the plasma stability of Chol-Suc-HA-DTX NPs was significantly influenced by the DS of hydrophobic moiety. The higher the DS was, the more stable the NPs were. Cellular uptake demonstrated that Chol-Suc-HA-DTX NPs were internalized into cancer cells via CD44 receptor-mediated endocytosis. Compared with Taxotere®, Chol-Suc-HA-DTX NPs displayed remarkably higher cytotoxicity to CD44-positive cancer cells (MCF-7, 4T1, A549 cells). In vivo animal experiments confirmed that Chol-Suc-HA-DTX NPs with relatively high DS values exhibited prolonged circulation time, excellent tumor-targeting properties and efficient antitumor effects with extremely low systemic toxicity. In addition, blank Chol-Suc-HA NPs also slightly suppressed the tumor growth.Conclusions
Chol-Suc-HA NPs with a suitable DS value portend to be promising drug vehicles for systemic targeting of CD44-overexpressed cancers.References
Articles referenced by this article (52)
A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery.
Biomaterials, (12):3087-3097 2013
MED: 23374705
Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
Biomaterials, (27):6393-6407 2012
MED: 22704599
Advances in polymeric micelles for drug delivery and tumor targeting.
Nanomedicine, (6):714-729 2010
MED: 20542144
Multifunctional drug delivery system for targeting tumor and its acidic microenvironment.
J Control Release, (3):884-892 2012
MED: 22587941
Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment.
Biomaterials, (33):8511-8520 2013
MED: 23932498
A pH-sensitive gene delivery system based on folic acid-PEG-chitosan - PAMAM-plasmid DNA complexes for cancer cell targeting.
Biomaterials, (38):10120-10132 2013
MED: 24094823
LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.
Biomaterials, (36):9171-9182 2013
MED: 24008043
Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells.
J Control Release, (1):201-206 2013
MED: 24008150
Biodegradable polymeric nanoparticles based drug delivery systems.
Colloids Surf B Biointerfaces, (1):1-18 2009
MED: 19782542
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.
Adv Drug Deliv Rev, (1):29-39 2011
MED: 21569804
Show 10 more references (10 of 52)
Citations & impact
Impact metrics
Article citations
Design of Bio-Responsive Hyaluronic Acid-Doxorubicin Conjugates for the Local Treatment of Glioblastoma.
Pharmaceutics, 14(1):124, 05 Jan 2022
Cited by: 13 articles | PMID: 35057020 | PMCID: PMC8781529
Lipopolysaccharide Nanosystems for the Enhancement of Oral Bioavailability.
AAPS PharmSciTech, 22(7):242, 30 Sep 2021
Cited by: 3 articles | PMID: 34595578
Review
Synthesis of Hyaluronic Acid-Conjugated Fe3O4@CeO2 Composite Nanoparticles for a Target-Oriented Multifunctional Drug Delivery System.
Micromachines (Basel), 12(9):1018, 26 Aug 2021
Cited by: 2 articles | PMID: 34577662 | PMCID: PMC8466504
Repurposing of Fluvastatin as an Anticancer Agent against Breast Cancer Stem Cells via Encapsulation in a Hyaluronan-Conjugated Liposome.
Pharmaceutics, 12(12):E1133, 24 Nov 2020
Cited by: 3 articles | PMID: 33255298 | PMCID: PMC7760927
Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology.
Dose Response, 18(3):1559325820936161, 10 Jul 2020
Cited by: 45 articles | PMID: 32699536 | PMCID: PMC7357073
Go to all (28) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.
Pharm Res, 31(4):1032-1045, 24 Oct 2013
Cited by: 27 articles | PMID: 24154802
GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Int J Nanomedicine, 11:5125-5147, 07 Oct 2016
Cited by: 15 articles | PMID: 27785019 | PMCID: PMC5066865
The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Biomaterials, 34(31):7662-7673, 13 Jul 2013
Cited by: 49 articles | PMID: 23859657
Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy.
Drug Discov Today, 22(4):665-680, 23 Dec 2016
Cited by: 61 articles | PMID: 28017836 | PMCID: PMC5413407
Review Free full text in Europe PMC